Trending Content - Off Topic Forum
| +27 | How do we get as sharp as possible? | 11 | 6h |
| +18 | Q&A | Analyst | 8 | 4d |
| +15 | Best way to kill time? | 10 | 15h |
| +15 | Upselling yourself when you’re unqualified | 2 | 15h |
| +13 | How Are Cornell 7 / GC Members Affecting Your Bank or Firm? | 5 | 1d |
| 0 | Analyst Y1 - Messed up In First Week | 2 | 15h |
Career Resources
Well, they aren't expected to generate positive EPS in 2012, so valuing them on a multiple basis isn't possible.
They missed on earnings and their arthritis drug isn't expected to generate top line growth til late 2012.
I don't know much more than that after a quick run through on them. Sounds like a 2013 story if anything, though.
don't know about that shit. if you want to play bio pick up DNDN, AMRN or AEZS, especially at theses levels.
it's been an adjustment in risk for all of the bio stocks since DNDN; worry is about the level of reimbursement from Medicaire for the high-priced drugs. Medicaire doesn't look to price / affordability only efficacy when it decides reimbursement. Obviously, that law can change if Medicaire is restructured.
disclosure: I'm obviously in all of them
Quibusdam similique sunt est. Voluptatem qui velit ratione dolores. Dicta et consequatur voluptatum velit tempora.
Voluptatibus est iste aperiam eius id amet. Qui consectetur molestias ipsa veniam provident voluptate non.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...